Showing all 3 results
Olmesartan Medoxomil Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly volatile ester prodrug.
Active Ingredient Strength Primary Clinical Function Olmesartan Medoxomil Ph.Eur./USP 20 mg Initiation / Global Standard: Standard adult starting and maintenance dose for the continuous control of essential hypertension. Olmesartan Medoxomil Ph.Eur./USP 40 mg Severe Refractory Standard: Maximum adult maintenance dose for patients requiring further reduction in blood pressure. Excipients Microcrystalline Cellulose / Lactose Monohydrate / Hydroxypropyl Cellulose / Magnesium Stearate / Titanium Dioxide Low-Moisture Diluent / Binder / Lubricant / Premium Moisture-Barrier Film-Coating (Engineered specifically to lock out ambient humidity and prevent the premature hydrolysis of the medoxomil group prior to ingestion) *Pack Sizes: 10×10 Alu-Alu Blisters or 3×10 Unit-Dose Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).
Perindopril Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Uncoated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips equipped with active desiccants to ensure the absolute chemical stability of the highly degradable Erbumine salt.
Active Ingredient Strength Primary Clinical Function Perindopril Erbumine Ph.Eur./USP 2 mg Initiation Standard: Base titration dose for elderly patients or those with severe heart failure/renal impairment to prevent sudden hypotension. Perindopril Erbumine Ph.Eur./USP 4 mg Hypertension Standard: Standard adult maintenance dose for the continuous control of essential hypertension. Perindopril Erbumine Ph.Eur./USP 8 mg Cardiovascular Risk Standard: Maximum maintenance dose for profound risk reduction in patients with stable coronary artery disease. Excipients Microcrystalline Cellulose / Lactose Anhydrous / Hydrophobic Colloidal Silica / Magnesium Stearate Diluent / Alkaline Stabilizer / Moisture Scavenger / Lubricant (Engineered specifically to create a hyper-dry internal tablet matrix that absolutely prevents hydrolytic cyclization of the API) *Pack Sizes: 10×10 Alu-Alu Blisters or 3×10 Unit-Dose Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).
Prasugrel Tablet
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips containing dedicated desiccants to ensure the absolute chemical stability of the highly volatile thienopyridine molecule.
Active Ingredient Strength Primary Clinical Function Prasugrel HCl INN/Ph.Eur. 5 mg Dose-Adjusted Standard: Maintenance dose strictly for vulnerable patients weighing < 60 kg or aged ≥ 75 years to minimize fatal bleeding risk. Prasugrel HCl INN/Ph.Eur. 10 mg Global Clinical Standard: Standard adult maintenance dose following a 60 mg acute loading dose in the Cath Lab. Excipients Microcrystalline Cellulose / Mannitol / Croscarmellose Sodium / Hypromellose / Triacetin Diluent / Superdisintegrant / Moisture-Barrier Film-Coating (Engineered specifically to prevent hydrolytic degradation and ensure ultra-fast gastric release) *Pack Sizes: 10×10 Alu-Alu Blisters or 28/30-Tablet Calendar Blisters (Optimized specifically for strict 12-month post-PCI dual-antiplatelet dispensing regimens).
